Avacta Group Plc

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: GB00BYYW9G87
GBP
0.60
0.01 (2.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

  • Poor long term growth as Operating profit has grown by an annual rate -190.89% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.65
2

Flat results in Jun 24

3

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 264 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

6.77

stock-summary
Return on Equity

-3,715.00%

stock-summary
Price to Book

264.05

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.86%
0%
-15.86%
6 Months
13.08%
0%
13.08%
1 Year
27.37%
0%
27.37%
2 Years
-42.38%
0%
-42.38%
3 Years
-62.45%
0%
-62.45%
4 Years
-36.46%
0%
-36.46%
5 Years
-52.53%
0%
-52.53%

Avacta Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
37.90%
EBIT Growth (5y)
-190.89%
EBIT to Interest (avg)
-13.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.92
Sales to Capital Employed (avg)
0.21
Tax Ratio
7.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
24.93
EV to EBIT
-7.81
EV to EBITDA
-8.95
EV to Capital Employed
12.60
EV to Sales
10.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-161.33%
ROE (Latest)
-470.11%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Avacta Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 139.18% vs 234.48% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 36.96% vs -49.62% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.20",
          "val2": "9.70",
          "chgp": "139.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.00",
          "val2": "-22.50",
          "chgp": "-2.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "15.30",
          "val2": "2.70",
          "chgp": "466.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "14.90",
          "val2": "-10.10",
          "chgp": "247.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.90",
          "val2": "-39.50",
          "chgp": "36.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,149.30%",
          "val2": "-2,640.90%",
          "chgp": "149.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'23stock-summary

Dec'23
Dec'22
Change(%)
Net Sales
23.20
9.70
139.18%
Operating Profit (PBDIT) excl Other Income
-23.00
-22.50
-2.22%
Interest
15.30
2.70
466.67%
Exceptional Items
14.90
-10.10
247.52%
Consolidate Net Profit
-24.90
-39.50
36.96%
Operating Profit Margin (Excl OI)
-1,149.30%
-2,640.90%
149.16%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 139.18% vs 234.48% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 36.96% vs -49.62% in Dec 2022

stock-summaryCompany CV
About Avacta Group Plc stock-summary
stock-summary
Avacta Group Plc
Miscellaneous
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Company Coordinates stock-summary
Company Details
Unit 20, Ash Way , WETHERBY None : LS23 7FA
Registrar Details